Cerecor Priced, Nasdaq: CERC

Developing a novel adjunct therapy for major depressive disorder.

Industry: Health Care

Latest Trade: $0.62 0.00 (0.0%)

First Day Return: -1.5%

Return from IPO: -90.5%

Industry: Health Care

We are a clinical stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders. We have a portfolio of clinical and preclinical compounds that we believe are best in class and where human proof of concept has been established for the compound or the target. We are currently pursuing regulatory approval of three product candidates: CERC-301 (major depressive disorder), CERC-501 (substance use disorders) and CERC-406 (residual cognitive impairment).
more less
IPO News for Cerecor
more
IPO Data
IPO File Date 06/12/2015
Offer Price $6.50
Price Range $6.00 - $7.00
Offer Shares (mm) 4.0
Deal Size ($mm) $26
IPO Data
IPO Date 10/15/2015
Offer Price $6.50
Price Range $6.00 - $7.00
Offer Shares (mm) 4.0
Deal Size ($mm) $26
Underwriters
more
Company Data
Headquarters Baltimore, MD
Founded 2011
Employees 11
Website www.cerecor.com